Harvard Medical School researchers, led by Associate Professor Marinka Zitnik, introduced COMPASS, an AI model designed to predict patient responses to immune checkpoint inhibitor (ICI) therapy. The report positions COMPASS as a tool to improve selection of likely responders and reduce trial-and-error in oncology immunotherapy by extracting signal from clinical and biomarker data.